Cargando…

Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies

Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guohao, Qiu, Yanmei, Zhang, Po, Chen, Zirong, Chen, Sui, Huang, Weida, Wang, Baofeng, Yu, Xingjiang, Guo, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502387/
https://www.ncbi.nlm.nih.gov/pubmed/36145510
http://dx.doi.org/10.3390/pharmaceutics14091762
_version_ 1784795692555829248
author Liu, Guohao
Qiu, Yanmei
Zhang, Po
Chen, Zirong
Chen, Sui
Huang, Weida
Wang, Baofeng
Yu, Xingjiang
Guo, Dongsheng
author_facet Liu, Guohao
Qiu, Yanmei
Zhang, Po
Chen, Zirong
Chen, Sui
Huang, Weida
Wang, Baofeng
Yu, Xingjiang
Guo, Dongsheng
author_sort Liu, Guohao
collection PubMed
description Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG.
format Online
Article
Text
id pubmed-9502387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95023872022-09-24 Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies Liu, Guohao Qiu, Yanmei Zhang, Po Chen, Zirong Chen, Sui Huang, Weida Wang, Baofeng Yu, Xingjiang Guo, Dongsheng Pharmaceutics Review Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG. MDPI 2022-08-24 /pmc/articles/PMC9502387/ /pubmed/36145510 http://dx.doi.org/10.3390/pharmaceutics14091762 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Guohao
Qiu, Yanmei
Zhang, Po
Chen, Zirong
Chen, Sui
Huang, Weida
Wang, Baofeng
Yu, Xingjiang
Guo, Dongsheng
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title_full Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title_fullStr Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title_full_unstemmed Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title_short Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
title_sort immunogenic cell death enhances immunotherapy of diffuse intrinsic pontine glioma: from preclinical to clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502387/
https://www.ncbi.nlm.nih.gov/pubmed/36145510
http://dx.doi.org/10.3390/pharmaceutics14091762
work_keys_str_mv AT liuguohao immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT qiuyanmei immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT zhangpo immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT chenzirong immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT chensui immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT huangweida immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT wangbaofeng immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT yuxingjiang immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies
AT guodongsheng immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies